Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib

Abstract Patients with non‐small cell lung cancer (NSCLC) and uncommon epidermal growth factor receptor (EGFR) mutation are characterized by high heterogeneity, and globally considered to have a worse prognosis than patients with the two common mutations; exon 19 deletion, and exon 21 L858R. Neverth...

Full description

Bibliographic Details
Main Authors: Vito Longo, Annamaria Catino, Michele Montrone, Pamela Pizzutilo, Francesco Pesola, Ilaria Marech, Iolanda Capone, Arsela Prelaj, Domenico Galetta
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Thoracic Cancer
Subjects:
compound EGFR mutations
kinase inhibitors
tyrosine
uncommon EGFR mutations
Online Access:https://doi.org/10.1111/1759-7714.13953

Internet

https://doi.org/10.1111/1759-7714.13953

Similar Items